Search results
Results from the WOW.Com Content Network
A549 cells are adenocarcinomic human alveolar basal epithelial cells, and constitute a cell line that was first developed in 1972 by D. J. Giard, et al. through the removal and culturing of cancerous lung tissue in the explanted tumor of a 58-year-old caucasian male. [1]
To further confirm that endogenous wild-type p53 is really causing the repression of survivin gene expression, the authors induced A549 (human lung cancer cell line with wild-type p53) and T47D (human breast cancer cell line with mutant p53) cells with DNA-damaging agent adriamycin to trigger the physiological p53 apoptotic response in these ...
In the 1960s, small cell lung carcinoma (SCLC) was recognized as a unique form of lung cancer, based both on its appearance and its clinical properties, including much greater susceptibility to chemotherapy and radiation, more rapid growth rate, and its propensity to metastasize widely early on in its course.
Most immortalised cell lines are classified by the cell type they originated from or are most similar to biologically 3T3 cells – a mouse fibroblast cell line derived from a spontaneous mutation in cultured mouse embryo tissue. A549 cells – derived from a cancer patient lung tumor
A549 cells share the same characteristics with the alveolar type II cells. This are type II pneumocytes crucial for lung homeostasis, and regeneration upon damage. For research purposes to unravel different molecular mechanisms leading to lung diseases, A549 cells serves as a good model to which translational research can be relied upon.
Confocal images of human lung cancer cells treated with discodermolide. Note the extreme rearrangement of the microtubule network and the breakdown of the cell nucleus. This rearrangement is irreversible and blocks the cell from dividing, and thus eventually leading to cell death.
Here’s how to get rid of chest congestion medically and naturally, according to experts.
Pie chart showing incidence of large-cell lung cancer (shown in green at upper left) as compared to other lung cancer types, with fractions of smokers versus non-smokers shown for each type. [ 7 ] In most series, LCLC's comprise between 3%-9% of all primary lung cancers .